AR054615A1 - Tetrahidroquinolinas - Google Patents
TetrahidroquinolinasInfo
- Publication number
- AR054615A1 AR054615A1 ARP060102410A ARP060102410A AR054615A1 AR 054615 A1 AR054615 A1 AR 054615A1 AR P060102410 A ARP060102410 A AR P060102410A AR P060102410 A ARP060102410 A AR P060102410A AR 054615 A1 AR054615 A1 AR 054615A1
- Authority
- AR
- Argentina
- Prior art keywords
- nnr2
- naryl
- nheteroaryl
- nxr
- aryl
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- VIESAWGOYVNHLV-UHFFFAOYSA-N 1,3-dihydropyrrol-2-one Chemical compound O=C1CC=CN1 VIESAWGOYVNHLV-UHFFFAOYSA-N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 abstract 1
- 101100277337 Arabidopsis thaliana DDM1 gene Proteins 0.000 abstract 1
- 241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 1
- 101000974340 Homo sapiens Nuclear receptor corepressor 1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101100410801 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pxr-1 gene Proteins 0.000 abstract 1
- 102100022935 Nuclear receptor corepressor 1 Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 101150113676 chr1 gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Compuestos de formula (1), donde: W es CH o N; R 1, R2, R3 independientemente entre sí, H, A, arilo, heteroarilo, Hal, -(CY2)n-SA, -(CY2)n-SCF3, -(CY2)n-SCN, -(CY2)n-CF3, -(CY2)n-OCF3, cicloalquilo, -SCH3, -SCN, -CF3, -OCF3, -OA, -(CY2)n-OH, -(CY2)n- CO2R, -(CY2)n-Hal, -(CH2)nR, -(CY2)n-NR2, -(CY2)n-OR, -(CY2)n-OCOA, -SCF3, -(CY2)n-CONR2, -(CY2)n-NHCOA, -(CY2)n-NHSO2A, SF5, Si(CH3)3, CO-(CY2)n-CH3, -(CY2)n-N-pirrolidona, -(CH2)nNRCOOR, NRCOOR, NCO, CH2(CH2)nCOOR, NHCOOR, CH2-(CH2)n-OH, - NR(CH2)nOH, CH2NH2, (CH2)nNR2, CH(OH)R2, CH2NHCOR, (CH2)narilo, CH2(CH2)nheteroarilo, (CH2)nR1, NH(CH2)nCOOR, CH2(CH2)nX(CH2)narilo, (CH2)(CH2)nX(CH2)nheteroarilo, NH(CH2)nCONR2, XCONR(CH2)nNR2, N[(CH2)nXCOOR]CO(CH2)narilo, N[(CH2)nXR]CO(CH2)narilo, N[(CH2)nXR]CO(CH2)nX-arilo, N[(CH2)nXR]SO2(CH2)narilo, N[(CH2)nNRCOOR]CO(CH2)narilo, N[(CH2)nNR2]CO(CH2)narilo, N[(CH2)nNR2]CO(CH2)nNR-arilo, N[(CH2)nNR2]SO2(CH2)narilo, N[(CH2)nXR]CO(CH2)nheteroarilo, N[(CH2)nXR]CO(CH2)nX-heteroarilo, N[(CH2)nXR]SO2(CH2)nheteroarilo, N[(CH2)nNRCOOR]CO(CH2)nheteroarilo, N[(CH2)nNR2]CO(CH2)nheteroarilo, N[(CH2)nNR2]CO(CH2)nNR-heteroarilo, donde grupos CY2 no vecinas también pueden estar reemplazadas por X, R1, y R3 conjuntamente también pueden significar -N-C(CF3)=N-, -N-CR=N-, -N-N=N-; Y es H, A, Hal, OR1, N(R1)2, E-R1; A es alquilo o cicloalquilo, donde uno o varios átomos de H pueden estar reemplazados por Hal y/o uno o varios grupos CH2 no vecinos pueden estar reemplazados por X; Hal es F, Cl, Br o I; R es H o A, en residuos geminales conjuntamente también -(CH2)5-, -(CH2)4-, o -(CH2)n-X-(CH2)n, o -(CH2)n-Z-(CH2)n; R4 es H ; R5 es independientemente entre sí, H o N-pirrolidona no substituida o substituida una o varias veces con OR, NO2, Hal, CF3, OCF3, CN, NR2, o SR, arilo o heteroarilo, -X-(CH2)2OR, -X-CO(CH2)nCH3, -X-(CH2)2NR2, R1, S-arilo, O-arilo, CH2Si(CH3)3, Q, -(CY2)n-E-CR2R1, -(CY2)n-E-CR2XR1, -(CY2)n-E-(CY2)n-XR1 o -(CY2)n-E-(CY2)n-XRa; E es -NR1SO2-, -SO2NR1-, - CONR1-, NR1CO-, -COO-, -OOC-, -NR1CONR1-, OCONR1-, -NR1COO-, -CSNR1-, -NR1CS-, -NR1CSNR1-, -SCONR1-, -NR1COS_, -OCSNR1-, -NR1CSO-, -SCSNR1-, -NR1CSS- o una ligadura simple; X es O, S, o NR1; Q es (CH2)pHal, CHO, CORa, (CH2)pRa, (CH2)pOCORa, (CH2)pXR1, (CH2)pNCOR1, (CH2)pN(R1)2, (CH2)pOR1, (CH2)pOCON(R1)2, (CH2)pOCOOR1, (CH2)pNHCON(R1)2, (CH2)pNHCOOR1, (CH2)pCN, (CH2)pCOOR1, (CH2)p-E-(CH2)pR1, (CH2)p-E-(CH2)pRa, donde grupos CH2 no vecinos también pueden estar reemplazados por X; o es un resto seleccionado del grupo de formulas (2); o es OR, NHR, NR2, NR(CH2)narilo, NR(CH2)nOR, COOR, N-residuo de pirrolidona, OCOR, NR(CH2)nR2, N[(CH2)nNR2]CO(CH2)narilo, N[(CH2)nNHCOOR]CO-arilo, R1, N[CH2(CH2)nOR]2, NR(CH2)nNCOOR, X(CH2)nX(CH2)nXR, NR(CH2)nX(CH2)nOH, NR(CH2)nO(CH2)nOH, (CH2)nCOOR, O(CO)NR(CH2)nOR, O(CO)(CH2)nNR2, NR(CH2)nNR2, N[(CH2)nNR2]CO(CH2)narilo, N[(CH2)nXR]CO(CH2)narilo, N[(CH2)nXR]CO(CH2)nheteroarilo, N[(CH2)nNR2]CO(CH2)nheteroarilo, N[(CH2)nNR2]CO(CH2)nR1, N(R)(CH2)nN(R)COOR, XCOO(CH2)nNR2, OSO2A, OSO2CF3, OSO2Ar, OCONR2, OCH2(CH2)nNR2; Z es CH2, X, CHCONH2, CH(CH2)nNR1COOR1, CHNR1COOR1, CHCON(R1)2, NCO, CH(CH2)nCOOR1, NCOOR1, CH(CH2)nOH, N(CH2)nOH, CHNH2, CH(CH2)nN(R1)2, C(OH)R1, CHNCOR1, NCOR1, N(CH2)narilo, N(CH2)nheteroarilo, CHR1, NR1, CH(CH2)narilo, CH(CH2)nheteroarilo, CH(CH2)nR1, N(CH2)nCOOR1, CH(CH2)nX(CH2)nR1, CH(CH2)nX(CH2)nRa, N(CH2)nCON(R1)2, XCONR1(CH2)nN(R1)2, CO(CH2)nR1, CO(CH2)nR1, CO(CH2)nXR1, SO2(CH2)nR1, O(CH2)nN(R1)2, X(CH2)nN(R1)2, NCO(CH2)nN(R1)2, CHRa, NRa; R6 es arilo o heteroarilo no substituido o substituido una o varias veces por arilo o héteroarilo, que puede estar substituido por Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2, Hal, NO2, CN, OR, -(CY2)n-OR, -OCOR, -(CY2)n-CO2R, -(CY2)n-CN, -NCOR, -COR o -(CY2)n-NR2; R7 es (C=O)-R, (C=O)-NR2, (C=O)-OR, H o A, donde R5 y R7 conjuntamente también pueden significar -(CH2)n-; m es 0, 1 o 2, n es 0, 1, 2, 3, 4, 5, 6 o 7, y p es 0, 1, 2, 3, 4 o 5, preferentemente 2 o 3, s es 0, 1, 2, 3, 4, 5, 6 o 7, preferentemente 0; como así también sus derivados, solvatos, tautomeros, sales y estereoisorneros farmacéuticamente utilizables, incluyendo sus mezclas en todas las proporciones. Pueden ser utilizados, entre otros, para el tratamiento de tumores.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005027168A DE102005027168A1 (de) | 2005-06-13 | 2005-06-13 | Tetrahydrochinoline |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054615A1 true AR054615A1 (es) | 2007-07-04 |
Family
ID=36870019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060102410A AR054615A1 (es) | 2005-06-13 | 2006-06-09 | Tetrahidroquinolinas |
Country Status (15)
Country | Link |
---|---|
US (1) | US8207345B2 (es) |
EP (1) | EP1891011B1 (es) |
JP (1) | JP5420898B2 (es) |
AR (1) | AR054615A1 (es) |
AT (1) | ATE490957T1 (es) |
AU (1) | AU2006257414B2 (es) |
CA (1) | CA2611893C (es) |
CY (1) | CY1111432T1 (es) |
DE (2) | DE102005027168A1 (es) |
DK (1) | DK1891011T3 (es) |
ES (1) | ES2357625T3 (es) |
PL (1) | PL1891011T3 (es) |
PT (1) | PT1891011E (es) |
SI (1) | SI1891011T1 (es) |
WO (1) | WO2006133821A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005027170A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Substituierte Tetrahydrochinoline |
DE102006060598A1 (de) * | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Tetrahydrobenzoisoxazole |
DE102007013854A1 (de) * | 2007-03-20 | 2008-09-25 | Merck Patent Gmbh | Tetrahydrochinoline |
TW200934785A (en) | 2007-10-19 | 2009-08-16 | Schering Corp | Compounds for inhibiting KSP kinesin activity |
JP2013075830A (ja) * | 2010-02-03 | 2013-04-25 | Taisho Pharmaceutical Co Ltd | キノリン誘導体 |
US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0395117A (ja) * | 1989-06-13 | 1991-04-19 | Kyorin Pharmaceut Co Ltd | 代謝性骨疾患治療剤 |
DK0550635T3 (da) * | 1990-09-28 | 1995-09-04 | Pfizer | Cykliske forbindelser med kondeserede ringe, som er analoger til nitrogenholdige ikke-aromatiske het erocykliske forbindelser |
GB9216911D0 (en) * | 1992-08-10 | 1992-09-23 | Merck Sharp & Dohme | Therapeutic agents |
WO1997030054A1 (en) | 1996-02-15 | 1997-08-21 | Cambridge Neuroscience, Inc. | Pharmaceutically active compounds and methods of use |
FR2760237B1 (fr) * | 1997-02-28 | 1999-04-16 | Rhone Poulenc Rorer Sa | Thiazolobenzoheterocycles, leur preparation et les medicaments les contenant |
US6180640B1 (en) * | 1998-06-25 | 2001-01-30 | Sepracor, Inc. | Di- and tetra-hydroquinoline-indole antimicrobial agents, uses and compositions related thereto |
JP2000072773A (ja) * | 1998-08-28 | 2000-03-07 | Zeria Pharmaceut Co Ltd | プリン誘導体 |
DE60210283T2 (de) * | 2001-05-22 | 2006-11-09 | Eli Lilly And Co., Indianapolis | 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren |
ITMI20012060A1 (it) * | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
WO2004072041A1 (en) * | 2003-02-12 | 2004-08-26 | Care X S.A. | Tetrahydroquinolines as agonists of liver- x receptors |
KR20050107784A (ko) | 2003-03-07 | 2005-11-15 | 아스트라제네카 아베 | 신규한 융합 복소환 및 이의 용도 |
CN1194969C (zh) * | 2003-05-30 | 2005-03-30 | 中国科学院大连化学物理研究所 | 对映选择性铱催化氢化取代芳香吡啶环和吡嗪环的方法 |
DE102005027170A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Substituierte Tetrahydrochinoline |
-
2005
- 2005-06-13 DE DE102005027168A patent/DE102005027168A1/de not_active Withdrawn
-
2006
- 2006-06-02 JP JP2008516172A patent/JP5420898B2/ja not_active Expired - Fee Related
- 2006-06-02 CA CA2611893A patent/CA2611893C/en not_active Expired - Fee Related
- 2006-06-02 EP EP06754091A patent/EP1891011B1/de not_active Not-in-force
- 2006-06-02 AU AU2006257414A patent/AU2006257414B2/en not_active Ceased
- 2006-06-02 SI SI200630942T patent/SI1891011T1/sl unknown
- 2006-06-02 PT PT06754091T patent/PT1891011E/pt unknown
- 2006-06-02 AT AT06754091T patent/ATE490957T1/de active
- 2006-06-02 ES ES06754091T patent/ES2357625T3/es active Active
- 2006-06-02 WO PCT/EP2006/005297 patent/WO2006133821A1/de active Application Filing
- 2006-06-02 DE DE502006008473T patent/DE502006008473D1/de active Active
- 2006-06-02 PL PL06754091T patent/PL1891011T3/pl unknown
- 2006-06-02 US US11/917,309 patent/US8207345B2/en active Active
- 2006-06-02 DK DK06754091.4T patent/DK1891011T3/da active
- 2006-06-09 AR ARP060102410A patent/AR054615A1/es unknown
-
2011
- 2011-03-02 CY CY20111100245T patent/CY1111432T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006257414A1 (en) | 2006-12-21 |
AU2006257414B2 (en) | 2011-08-25 |
DK1891011T3 (da) | 2011-03-21 |
DE502006008473D1 (de) | 2011-01-20 |
JP2008545805A (ja) | 2008-12-18 |
PT1891011E (pt) | 2011-03-11 |
US8207345B2 (en) | 2012-06-26 |
CA2611893C (en) | 2013-12-17 |
WO2006133821A1 (de) | 2006-12-21 |
ATE490957T1 (de) | 2010-12-15 |
SI1891011T1 (sl) | 2011-04-29 |
JP5420898B2 (ja) | 2014-02-19 |
CY1111432T1 (el) | 2015-08-05 |
EP1891011A1 (de) | 2008-02-27 |
ES2357625T3 (es) | 2011-04-28 |
CA2611893A1 (en) | 2006-12-21 |
DE102005027168A1 (de) | 2006-12-14 |
PL1891011T3 (pl) | 2011-05-31 |
US20080200451A1 (en) | 2008-08-21 |
EP1891011B1 (de) | 2010-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054615A1 (es) | Tetrahidroquinolinas | |
AR054616A1 (es) | Tetrahidroquinolinas sustituidas | |
AR077974A1 (es) | Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor | |
AR040514A1 (es) | Heterociclos diarilicos sustituidos, procedimiento para la preparacion de medicamentos y la utilizacion de los compuestos para tal fin | |
AR056863A1 (es) | Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas, metodos de preparacion y usos de los mismos | |
CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
AR067316A1 (es) | Moleculas secuestradoras de oxigeno, articulos que las contienen y metodos para su uso | |
AR050994A1 (es) | N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas, y composicion farmaceutica en base al compuesto | |
PE20220387A1 (es) | Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancer | |
AR083635A1 (es) | Compuestos y derivados sustituidos de isoxazolina que contienen azolin para combatir plagas animales | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
ES2621407T3 (es) | Ciclohexildiaminas sustituidas | |
AR062357A1 (es) | Derivados de fenilo, piridina y quinolina, composiciones farmaceuticas y su utilizacion como medicamentos | |
AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
AR072373A1 (es) | Tiadiazoliloxifenilamidinas, el uso de las mismas como fungicidas en composiciones y metodos de uso, proceso para su preparacion e intermediarios de sus sintesis. | |
AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
AR049701A1 (es) | Aminas terciarias no imidazolicas que actuan como inhibidores del receptor de histamina 3 para el tratamiento de trastornos cognitivos y del sueno, obesidad y otros trastornos del snc | |
PE20230618A1 (es) | Analogos de nucleosido de 1'-ciano y usos de los mismos | |
DOP2010000022A (es) | Derivados de pirimidina 934 | |
AR041941A1 (es) | Derivado de 1-aminociclohexano sustituidos en la posicion 4 utilizado como receptor orl1 | |
CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
AR079467A1 (es) | Derivados heterociclicos nitrogenados de etinilo, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para tratar y/o prevenir enfermedades cognitivas o esquizofrenia. | |
PE20090817A1 (es) | Inhibidores de la interaccion entre mdm2 y p53 | |
PE20141940A1 (es) | Compuestos triciclicos, composiciones que los comprenden y usos de los mismos | |
AR054282A1 (es) | Derivados de tetrahidroquinolina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |